About SACHI BIOWORKS, INC.
Sachi Bio is a biotechnology company focused on developing RNA therapeutic technologies, particularly for neurodegenerative diseases such as Alzheimer's and Dementia. The company utilizes Nanoligomer technology to create brain-penetrant, targeted therapies with high specificity and minimal off-target effects.
Rapid drug discovery using brain-penetrant targeted moleculesHigh specificity and low off-target effectsMultiplexing and multidimensional target identificationAccelerated design, synthesis, validation, and production of targeted therapies
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE | National Aeronautics and Space Administration | $5.4M | |
| Federal contract award | National Aeronautics and Space Administration | $166K | |
| E014042 SBIR PHASE II REVERSING IMMUNE DYSREGULATION DURING SPACEFLIGHT MISSIONS | National Aeronautics and Space Administration | $2.0M | |
| SBIR PHASE III - REVERSING IMMUNE DYSREGULATION DURING SPACEFLIGHT MISSIONS | National Aeronautics and Space Administration | $2.2M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to SACHI BIOWORKS, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.